Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Cardiotoxicity of first-line chemotherapy in patients with advanced non-small cell lung cancer

EuroSciCon Conference on Oncology and Cancer Stem Cell
November 05-06 , 2018 Paris , France

Daliborka S Bursac

Institute for pulmonary diseases of Vojvodina, Serbia, University of Novi Sad, Serbia

Scientific Tracks Abstracts: Arch Cancer Res


Cardiotoxicity occurs during therapy with several cytotoxic agents and may be the dose limiting factor in cancer treatment. Furthermore, it can also be responsible for long term side effects and may cause severe morbidity in surviving cancer patients. Chemotherapy induced cardiotoxicity is not common but significant complication in patients with lung cancer. The aim of this study was to establish the frequency of cardiotoxicity in the patients treated with the first-line chemotherapy (gemcitabine/cisplatin and paclitaxel/ carboplatin). This prospective study included 240 patients with cytologically or histopathologically confirmed non-small cell lung cancer (NSCLC) at the clinical stages III and IV. Cardiac toxicity was determined based on the presence of cardiovascular symptoms, changes in the electrocardiogram, elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin T and a decrease in left ventricular ejection fraction. Most common cardiovascular toxic effects were increase in the level of NT-proBNP (44.85%), cardiac arrhythmias (26.18%), venous thromboembolism (19.9%) and decreased left ventricular ejection fraction (6.96%). Chemotherapy induced cardiotoxocity frequently occurs in patients with cardiovascular comorbidities. Patients with cancer, particularly those with known cardiac risk factors are at risk for development of cardiotoxicity and need careful assessment before initiation of chemotherapy. Balance between the effectiveness of chemotherapy and the risk of cardiotoxicity requires close cooperation of oncologists and cardiologists.

Biography :

Daliborka Bursac has completed her PhD from University of Novi Sad, Serbia. She is the Head of the Daily Hospital for the application of chemotherapy in the Institute for pulmonary diseases of Vojvodina in Sremska Kamenica. Also, she is the Assistant Professor of the Faculty of Medicine, University of Novi Sad. She has published more than 40 papers in reputed journals and has been serving as an Editorial Board Member of repute.

E-mail: [email protected]